invivodata Announces Improved SitePRO Solution for Site-Based ePRO Assessments
invivodata offers large-screen SitePRO solution to deliver reliability and cost savings.
Pittsburgh, PA— May 19, 2008—invivodata inc. (www.invivodata.com), the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced the launch of its improved SitePRO® solution for in-clinic PRO assessments. The SitePRO Tablet, invivodata’s second-generation large-screen solution, meets sponsor goals to automate paper-based site assessments and enables clinical trial sponsors to manage both site- and patient-based assessment data in a single source.
The SitePRO Tablet utilizes the same, proven invivodata SitePRO software used successfully in dozens of site-based ePRO studies and is the industry’s only site-based ePRO solution to have collected primary efficacy data in support of a successful New Drug Application (NDA). It runs on a Microsoft Windows device that contains a full-sized, 12-inch display screen and offers significant advantages over other currently available site-based ePRO solutions, including these:
- Accurately captures lengthy quality-of-life and other in-clinic-based assessments in either portrait or landscape mode.
- Allows for more accurate transition from paper to electronic assessments and handles large scales without compromise.
- The migration of a paper scale to a SitePRO Tablet in many cases will not require a modification to the core assessment layout, reducing or eliminating validation costs.
“We are pleased to offer this larger screen solution to meet our customers’ in-clinic PRO assessment needs,” said Tom Henson, invivodata vice president of marketing. “And we are confident that the SitePRO Tablet’s multiple data transfer options will provide the flexibility that investigative site personnel require, making it easy for them to capture and transfer PRO data during clinical trials.”
invivodata will demonstrate the SitePRO Tablet, which is now available for clinical trials, at the Drug Information Association (DIA) Annual Meeting in Boston, June 22–25, 2008 in Booth 600.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
